Username Password  
Forgotten password

Latest News


18th December 2018 - Recall - potential contamination

APO-Valsartan (valsartan) tablets

Consumers and health professionals are advised that Apotex, in consultation with the TGA, is recalling all batches of all strengths of APO-Valsartan tablets (40 mg, 80 mg, 160 mg and 320 mg) due to the presence of trace amounts of an impurity.

These valsartan-containing products are used to treat high blood pressure (also known as hypertension) and other heart-related disorders.

The impurity detected was N nitrosodiisopropylamine (NDIPA), which belongs to the N nitroso chemical class that is known to contain mutagens and carcinogens (substances that could potentially cause cancer). However, based on the information available to Apotex to date, the company has advised that it expects the health risk from use of affected APO-Valsartan tablets is very low.

Full alert available:



18th July 2018 - Safety Advisory

Sodium glucose co-transporter 2 inhibitors, diabetic ketoacidosis and surgical procedures

Consumers and health professionals are advised that the TGA is working with sponsors of sodium glucose co-transporter 2 (SGLT2) inhibitors to update medicine information documents to strengthen warnings about the risk of diabetic ketoacidosis with these medicines. In particular, the risk is increased in people who undergo surgical or medical procedures. This action has been prompted by an increase in the number of local reports received by the TGA of diabetic ketoacidosis occurring in people being treated with these medicines in Australia.

SGLT2 inhibitors currently marketed in Australia are dapagliflozin and empagliflozin. Brand names for dapagliflozin-containing products are Forxiga, Qtern and Xigduo XR. Brand names for empagliflozin-containing products are Jardiance, Jardiamet and Glyxambi.

Factors that predispose diabetic patients to ketoacidosis include:
  • surgery
  • acute illness, particularly infections
  • insulin dose reduction
  • a low carbohydrate diet
  • malnourishment/reduced caloric intake
  • severe dehydration
  • previous ketoacidosis
  • insulin deficiency from any cause (such as insulin pump failure, history of pancreatitis or pancreatic surgery)
  • alcohol abuse

18th May 2018 - Successful Accreditations

Congratulations to our various partners; Aurrum Wyoming, McKenzie The Ashley, Aurrum Healesville, Brentwood, Mercy Colac, Magnolia Aged Care and Costa House for successful accreditations through their demonstration of high quality aged care.

11th May 2018 - New Education Topic

Why are there so many puffers? Why is this puffer purple? How does this puffer work?... Find yourself asking these questions?

Ask your Mederev consultant pharmacist today for an education session on Asthma, COPD and Inhalers.

A comprehensive session to ensure familiarity with the numerous amounts of puffers available on the market.

Asthma, COPD and Inhalers

1-Asthma overview

2-Medicines in Asthma

3-COPD overview

4-Medicines in COPD

5-Types of Inhalers

6-Common problems

7-Inhaler technique 

RN, EN & Carers

45 & 2 handouts


20th April 2018 - Flu Vaccine Safety Alert (TGA)

May all facility staff please be advised that, for the 2018 influenza season, natural rubber latex is present in the sheath covering the needle of trivalent influenza vaccine Fluad. Flaud is available for people aged 65 years and over through the National Immunisation Program (NIP) and may be chosen to be administered to your residents.

While reactions to latex are rare, anyone who has a severe allergy to latex should not receive Fluad. Residents 65 and over can still be safely vaccinated with an alternative trivalent influenza vaccine, Fluzone High-Dose through the NIP.

Please note there are no safety concerns regarding the vaccine itself.

4th April 2018 - Mederev and Monash University

Mederev is proud to be taking part in a Monash University – Centre for Medicine Use and Safety study examining “Antibiotic use at end-of-life in aged care homes”. The results from this study will help shape Antimicrobial Stewardship and influence how practitioners approach the use of antibiotics within aged care. The study is led by Dr David Kong and is supported by the National Centre for Antimicrobial Stewardship (NCAS). A peer reviewed paper will be made available before June 2018. Stay tuned!

6th March 2018 - Influenza Vaccination

For the 2018 influenza season, the TGA has registered six vaccines which will be available for use in the following age groups:



Age group

Quadrivalent vaccines


FluQuadri Junior*

6-35 months (<3 years)


3 years and over


Fluarix Tetra

3 years and over

Mylan Health

Influvac Tetra

18 years and over


Afluria Quad**

18 years and over

Trivalent vaccines


Fluzone High dose

65 years and over



65 years and over

The number one strategy to prevent an influenza epidemic is to obtain an influenza vaccination.

Every individual in aged care including all residents and staff should be vaccinated (unless contraindicated).

To complement the release of the Influenza Vaccination 2018, Mederev has created a comprehensive education presentation on Influenza Vaccination which can help increase the uptake of the important vaccine.

One of the major barriers to the uptake of the influenza vaccination is the lack of knowledge and incorrect beliefs in association with the vaccine. The Mederev education topic will alleviate all myths and fears.

Influenza Vaccination

1-Influenza Introduction



4-Clinical features


6-Vaccine Effectiveness

7-Vaccine Safety



RN, EN & Carers

32 slides


Please conttact your Mederev consultant pharmacist to book in an education session today! Remember to get that jab!

27th February 2018 - New Education Topic
A new “Nursing Practice” education topic is now available for in-house presentation by Mederev.
Time-Sensitive Medications
1-Basic Pharmacokinetics
3-Relationship of PK and time-sensitive medications
4-Medication administration times
5-Definition of time-sensitive medications
6-Why time-sensitive medications
7-List of time-sensitive medications
RN, EN & Carers
34 slides
Please contact your Mederev Consultant pharmacist to have an education session booked in at your facility.

13th February 2018 - Successful Accreditation
Congratulations to our partners Karingal St Lawrence Costa House (Lara, Geelong) ´╗┐and Opal Norah Head (NSW) for a successful accreditation. All medication management systems went very well.

19th January 2018 - Codeine
Please be diligent and remember for your residents that from 1 February 2018, medicines containing codeine will no longer be available without a prescription. Research shows that current over-the-counter low-dose (<30 mg) medicines containing codeine for pain relief offer very little additional benefit when compared to similar medicines without codeine. The use of such medicines however, is associated with high health risks. Please see more information from TGA here:

  6th December 2017 - Updated Medicine Ingredient Names
Some active ingredient names used in Australia differ from those used internationally. The Therapeutic Goods Administration (TGA) has updated over 200 active ingredient names used in Australia as part of their International Harmonisation of Ingredient Names (IHIN) reform. A full list is available on the TGA website. Around 90 of these changes affect medicines listed on the Pharmaceutical Benefits Scheme (PBS). These new names will be incorporated within the PBS during 2018.
A handy counselling tool (PDF 356KB) has been produced which provides a handy table of the most common changes that will be seen by consumers and health professionals during 2018. The tool confirms that while some ingredient names are changing, the actual medicine, brand name (in most cases) and the medicine’s effect have not changed.
While some of the changes to active ingredient names have already appeared in the PBS Schedule, the bulk of the changes to the Schedule will be incorporated during 2018, commencing 1 January 2018. Changes will subsequently appear in prescribing and pharmacy dispensing software products that use PBS Schedule data.
If there are any questions with the changes, ensure you contact your Mederev consultant before administering any doses that look unfamiliar.

  30th November 2017 - Opal Glenmere - Successful Accreditation
Congratulations to Opal Glenmere in NSW for passing their recent accreditation with flying colours, achieving 100% compliance in the component for medication management.

17th November  2017 - *TGA RECALL* - Additional batches of APO-Perindopril
A further eight batches of APO-Perindopril have been recalled. Please be vigilant!
See <> for more information.

  14th November 2017 - Successful Accreditation
Well done to McKenzie Sutton Park in Victoria for a successful accreditation. Rest assured, with Mederev, the medication management component of accreditation is fully and comprehensibly managed so that you will never be caught off guard.

13th November 2017 - New Education Topic
New Nursing Practice education topic “Administration of Sachet Medications” is available. Please also note there is an updated list of available education topics. Please contact your Mederev Consultant pharmacist to obtain a list or to arrange a time to have any of the topics presented at your facility.

  12th November  2017 - *TGA RECALL* - APO-PERINDOPRIL
Please be wary that TGA has issued a recall on three batches of a commonly used anti-hypertensive; Apo-Perindopril Arginine 2.5 mg, 5 mg and 10 mg tablets. If you notice this brand being used for any of your patients, please contact your supply pharmacy immediately. 


Web Design Gold Coast | Web Design Magic
© Copyright 2010. All rights reserved MedeRev
Home . Feedback . Newsletters . Privacy . Disclaimer . Contact Us . Site Map